arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MEDICINOVA INC

MNOV
$2.79 ▼ -0.15 (-5.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
78 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

MEDICINOVA INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $137.3M
Dividend Yield
Revenue Growth 240.6%
Op. Margin None
ROIC -5.4%
FCF / Share $-0.04
Trailing P/E
Price / Book 3.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$458.44K
↑ +240.6%
Net Income Profit after all expenses
$-2.59M
↑ +9.7%
Operating Margin Operating profit as % of sales
-114.7%
↓ -2176.4%
FCF / Share Free cash flow per share
$-0.04
↑ +44.8%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
24
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 26 years · 78 quarters